Table 2.
The effect of passively transferred immune serum (IS) from animals vaccinated with MVA-BN YF vaccine or with YF-VAX administered 24 h prior to challenge with YF virus.
| Toxicity controls | Infected, treated | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Treatment | Dose | Serum NeutAb titera | Alive/total | Serum alanine aminotransferase (ALT)b (IU/L) ± SD | Mean wt. changec (g) ± SD | Alive/total | MDDd ± SD | Serum ALTb (IU/L) ± SD | Mean wt. changec (g) ± SD |
| MVA-BN YF IS | 1:10 | 1.1 ± 0.2 | 3/3 | 67 ± 9.0 | 4.7 ± 2.1 | 8/10*** | 10.0 ± 0.0 | 88 ± 34 | 5.3 ± 3.4** |
| MVA-BN YF IS | 1:100 | <1.0 ± 0.0 | – | – | – | 4/10 | 8.5 ± 1.0 | 206 ± 82 | −7.5 ± 5.1 |
| YF-VAX IS | 1:10 | 1.0 ± 0.1 | 3/3 | 60 ± 6.0 | 6.0 ± 1.0 | 3/10 | 9.0 ± 1.5 | 162 ± 92 | −4.9 ± 5.3 |
| YF-VAX IS | 1:100 | 1.0 ± 0.1 | – | – | – | 1/10 | 8.4 ± 0.9 | 170 ± 89 | −7.5 ± 6.9 |
| Placebo IS | 1:10 | <1.0 ± 0.0 | 3/3 | 73 ± 19 | 6.0 ± 3.0 | 1/15 | 9.3 ± 1.5 | 169 ± 99 | −4.9 ± 8.3 |
| Norm. controls | – | 3/3 | 56 ± 6.0 | 4.7 ± 2.1 | – | – | – | – | |
aAverage log10 neutralizing antibody titer of serum collected 4 h prior to virus challenge and quantified by PRNT50.
bSerum ALT levels collected on 6 dpi.
cDifference between weight on 3 and 6 days post-virus challenge representing maximal weight change within this study.
dMean day to death of animals that succumb to disease during the experimental period of 21 days.
***p < 0.001, **p < 0.01, when compared with placebo treatment.